Subscribe
shutterstock_1661365084_sundry_photography
Sundry Photography / Shutterstock.com
17 February 2022Big Pharma

Roche and AstraZeneca units settle blood drug suit

Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Roche asks court for halt of Novartis unit’s generic launch
4 April 2022   Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.
Americas
AstraZeneca says Mylan, Kindeva infringe another Symbicort patent
28 April 2022   AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.
Americas
Chugai settles cancer drug patent dispute with US firm
10 August 2022   Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Roche asks court for halt of Novartis unit’s generic launch
4 April 2022   Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.
Americas
AstraZeneca says Mylan, Kindeva infringe another Symbicort patent
28 April 2022   AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.
Americas
Chugai settles cancer drug patent dispute with US firm
10 August 2022   Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

More on this story

Big Pharma
Roche asks court for halt of Novartis unit’s generic launch
4 April 2022   Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.
Americas
AstraZeneca says Mylan, Kindeva infringe another Symbicort patent
28 April 2022   AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.
Americas
Chugai settles cancer drug patent dispute with US firm
10 August 2022   Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York